{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:14:42Z","timestamp":1794280482304,"version":"4.9.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006751","name":"U.S. Army","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["OPP1112376"],"award-info":[{"award-number":["OPP1112376"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126828","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:01:26Z","timestamp":1738728086000},"page":"126828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Conserved antigens for enteric vaccines"],"prefix":"10.1016","volume":"50","author":[{"given":"Richard I.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2025.126828_bb0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0264-410X(94)90112-0","article-title":"New strategies for using mucosal vaccination to achieve more effective immunization","volume":"12","author":"Walker","year":"1994","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2025.126828_bb0010","first-page":"1211","article-title":"Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: A systematic analysis for the Global Burden of Disease Study 2016","volume":"2018","author":"GBD","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126828_bb0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: The Global Burden of Disease Study 1990\u20132016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126828_bb0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOP.0000000000001107","article-title":"Bacterial diarrhoea","volume":"34","author":"Kotloff","year":"2022","journal-title":"Curr Opin Pediatr"},{"issue":"49 Pt A","key":"10.1016\/j.vaccine.2025.126828_bb0025","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1016\/j.vaccine.2017.05.035","article-title":"Chronic consequences on human health induced by microbial pathogens: Growth faltering among children in developing countries","volume":"35","author":"Nataro","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126828_bb0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.pcl.2017.03.003","article-title":"Guerrant RL The Burden of Enteropathy and \u201cSubclinical\u201d Infections","volume":"64","author":"Rogawski","year":"2017","journal-title":"Pediatr Clin N Am"},{"key":"10.1016\/j.vaccine.2025.126828_bb0035","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2214-109X(18)30483-2","article-title":"Burden of enterotoxigenic Escherichia coli and Shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: A modelling analysis","volume":"7","author":"Anderson","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.126828_bb0040","author":"Wellcome Trust"},{"key":"10.1016\/j.vaccine.2025.126828_bb0045","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.12688\/f1000research.20100.1","article-title":"Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance\u2019s 2018 Vaccine Investment Strategy: Report from an expert survey","volume":"8","author":"Malarski","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.vaccine.2025.126828_bb0050","series-title":"Antibiotic Resistance Threats in the United States","year":"2019"},{"key":"10.1016\/j.vaccine.2025.126828_bb0055","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1016\/j.vaccine.2021.11.033","article-title":"World Health Organization expert working group: Recommendations for assessing morbidity associated with enteric pathogens","volume":"39","author":"Hasso-Agopsowicz","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126828_bb0060","first-page":"5","article-title":"Travelers\u2019 diarrhea: Update on the incidence, etiology and risk in military and similar populations - 1900-2005 versus 2005 - 2015, does a decade make a difference","author":"Olson","year":"2019","journal-title":"Tropical Diseases, Travel Medicine and Vaccines"},{"key":"10.1016\/j.vaccine.2025.126828_bb0065","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.3390\/ijerph19106138","article-title":"Effects of Climatic Factors on Diarrheal Diseases among Children below 5 Years of Age at National and Subnational Levels in Nepal: An Ecological Study","volume":"19","author":"Dhimal","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126828_bb0070","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/S2214-109X(23)00012-8","article-title":"Climate change and imperatives to ascertain causes of infectious diarrhoea in low-income and middle-income countries","volume":"11","author":"Dhimal","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.126828_bb0075","article-title":"Associations between eight Earth observation-derived climate variables and enteropathogen infection: An independent participant data meta analysis of surveillance studies with broad spectrum nucleic acid diagnostics","volume":"6","author":"Colston","year":"2022","journal-title":"GeoHealth 2022"},{"key":"10.1016\/j.vaccine.2025.126828_bb0080","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.vaccine.2023.03.003","article-title":"Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening","volume":"4","author":"Riddle","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126828_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125102","article-title":"Oral inactivated whole cell vaccine for mucosal immunization: ETVAX case study","volume":"14","author":"Walker","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0090","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.vaccine.2014.11.048","article-title":"Recommendations regarding the development of combined enterotoxigenic Escherichia coli and Shigella vaccines for infants","volume":"33","author":"Walker","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126828_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.13067","article-title":"A tale of two bacterial enteropathogens and one multivalent vaccine","volume":"21","author":"Barry","year":"2019","journal-title":"Cell Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126828_bb0100","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.vaccine.2006.11.012","article-title":"Vaccine potential for inactivated shigellae","volume":"25","author":"Osorio","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126828_bb0105","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/microorganisms9071382","article-title":"Vaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease","volume":"9","author":"Walker","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.126828_bb0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/microorganisms9020451","article-title":"The Shigella Type III Secretion System: An Overview from Top to Bottom","volume":"9","author":"Muthuramalingam","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.126828_bb0115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/IAI.06174-11","article-title":"Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins","volume":"80","author":"Martinez-Becerra","year":"2012","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126828_bb0120","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/vaccines10040548","article-title":"From Concept to Clinical Product: A Brief History of the Novel\u00a0Shigella\u00a0Invaplex Vaccine\u2019s Refinement and Evolution","volume":"10","author":"Turbyfill","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126828_bb0125","doi-asserted-by":"crossref","first-page":"e00260","DOI":"10.1128\/mSphere.00260-18","article-title":"A Novel Shigella Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge","volume":"3","author":"Ndungo","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.126828_bb0130","doi-asserted-by":"crossref","first-page":"e00988","DOI":"10.1128\/mSphere.00988-19","article-title":"Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G","volume":"5","author":"Clarkson","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.126828_bb0135","doi-asserted-by":"crossref","unstructured":"Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, Pasetti MF. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine. 2013; 31(28):2919-29. doi: https:\/\/doi.org\/10.1016\/j.vaccine.2013.04.045. Epub 2013 May 2. PMID: 23644075; PMCID: PMC3718310.","DOI":"10.1016\/j.vaccine.2013.04.045"},{"key":"10.1016\/j.vaccine.2025.126828_bb0140","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1128\/IAI.00859-13","article-title":"Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine","volume":"81","author":"Martinez-Becerra","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0145","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1016\/j.vaccine.2016.08.034","article-title":"Development of recombinant vaccine candidate molecule against Shigella infection","volume":"34","author":"Chitradevi","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126828_bb0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/CVI.00661-14","article-title":"Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection","volume":"22","author":"Kim","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/msphere.00073-23","article-title":"Development of the Shigella flexneri 2a, 3a, 6 and S. sonnei artificial Invaplex (InvaplexAR) vaccines","volume":"8","author":"Turbyfill","year":"2023","journal-title":"mSphere"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126828_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00583-17","article-title":"Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex","volume":"3","author":"Turbyfill","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.126828_bb0165","series-title":"Clinical Evaluation of\u00a0Shigella flexneri\u00a02a Detoxified Artificial Invaplex","author":"Clarkson","year":"2021"},{"key":"10.1016\/j.vaccine.2025.126828_bb0170","article-title":"A Novel Shigella O-Polysaccharide-IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes","volume":"5","author":"Desalegn","year":"2023","journal-title":"mSphere"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126828_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004749","article-title":"An O antigen capsule modulates bacterial pathogenesis in Shigella sonnei","volume":"20:11","author":"Caboni","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.126828_bb0180","series-title":"Controlled Human Infection Model Challenge\/Rechallenge: Shigella flexneri 2a and S. sonnei cross-protective antigens discovery in healthy adults in the United States ASTMH 72nd Annual Meeting October 18-22","author":"Talaat","year":"2023"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126828_bb0185","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/vaccines8040689","article-title":"Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC","volume":"8","author":"Harutyunyan","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126828_bb0190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/vaccines10020340","article-title":"Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated\u00a0Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial","volume":"10","author":"Girardi","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126828_bb0195","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.3389\/fmicb.2018.02609","article-title":"Cross-Protective\u00a0Shigella\u00a0Whole-Cell Vaccine with a Truncated O-Polysaccharide Chain","volume":"31","author":"Kim","year":"2018","journal-title":"Front Microbiol"},{"issue":"35","key":"10.1016\/j.vaccine.2025.126828_bb0200","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.vaccine.2011.05.021","article-title":"A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)","volume":"29","author":"Porter","year":"2011","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2025.126828_bb0205","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1016\/j.vaccine.2011.06.084","article-title":"A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression","volume":"29","author":"Isidean","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126828_bb0210","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00788-18","article-title":"Biochemical and Immunological Evaluation of Recombinant CS6-Derived Subunit Enterotoxigenic Escherichia coli Vaccine Candidates","volume":"87","author":"Poole","year":"2019","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126828_bb0215","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.vaccine.2015.11.017","article-title":"Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates","volume":"34","author":"Sincock","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126828_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00634-18","article-title":"Establishment, Validation, and Application of a New World Primate Model of Enterotoxigenic\u00a0Escherichia coli\u00a0Disease for Vaccine Development","volume":"87","author":"Rollenhagen","year":"2019","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126828_bb0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.vaccine.2020.12.034","article-title":"Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6\u00a0+\u00a0ETEC challenge model","volume":"39","author":"Ramakrishnan","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126828_bb0230","doi-asserted-by":"crossref","unstructured":"Lee T, Guti\u00e9rrez RL, Maciel M, Poole S, Testa KJ, Trop S, et al. Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli. Vaccine. 2021; 39(39):5548-5556. doi: https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.032. Epub 2021 Aug 18. PMID: 34419306; PMCID: PMC8461560.","DOI":"10.1016\/j.vaccine.2021.08.032"},{"key":"10.1016\/j.vaccine.2025.126828_bb0235","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3390\/microorganisms11112689","article-title":"A First in Human Clinical Trial Assessing the Safety and Immunogenicity of Two Intradermally Delivered Enterotoxigenic Escherichia coli CFA\/I Fimbrial Tip Adhesin Antigens with and without Heat-Labile Enterotoxin with Mutation LT(R192G)","volume":"11","author":"Guti\u00e9rrez","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.126828_bb0240","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/microorganisms12020288","volume":"12","author":"Gutierrez","year":"2024","journal-title":"Microorganisms"},{"issue":"49 Pt A","key":"10.1016\/j.vaccine.2025.126828_bb0245","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1016\/j.vaccine.2017.09.045","article-title":"Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference","volume":"35","author":"Walker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126828_bb0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41541-019-0131-7","article-title":"Interrogation of a live-attenuated enterotoxigenic\u00a0Escherichia coli vaccine highlights features unique to wild-type infection","volume":"4","author":"Chakraborty","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126828_bb0255","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/s41598-021-81895-0","article-title":"Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design","volume":"11","author":"Amcheslavsky","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126828_bb0260","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1473-3099(13)70297-4","article-title":"Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers\u2019 diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala","volume":"14","author":"Behrens","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2025.126828_bb0265","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.vaccine.2007.01.043","article-title":"Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study","volume":"25","author":"McKenzie","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126828_bb0270","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00253-010-2577-4","article-title":"Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA\/I and CS2 colonization fimbriae for use in vaccines","volume":"87","author":"Tobias","year":"2010","journal-title":"Appl Microbiol Biotechnol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126828_bb0275","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/IAI.00264-10","article-title":"Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins","volume":"78","author":"Roy","year":"2010","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126828_bb0280","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/toxins6061799","article-title":"Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli","volume":"6","author":"Fleckenstein","year":"2014","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.vaccine.2025.126828_bb0285","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/infdis\/jiy312","article-title":"Human Experimental Challenge with Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development","volume":"218","author":"Chakraborty","year":"2018","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126828_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003446","article-title":"Conservation and immunogenicity of novel antigens in diverse isolates of enterotoxigenic Escherichia coli","volume":"9","author":"Luo","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.126828_bb0295","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00248-16","article-title":"Fleckenstein JM Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin","volume":"23","author":"Luo","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"31","key":"10.1016\/j.vaccine.2025.126828_bb0300","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.vaccine.2021.04.018","article-title":"Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access","volume":"39","author":"Khalil","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126828_bb0305","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/CVI.00464-13","article-title":"Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli","volume":"20","author":"El-Kamary","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"35","key":"10.1016\/j.vaccine.2025.126828_bb0310","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.vaccine.2011.05.021","article-title":"A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)","volume":"29","author":"Porter","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126828_bb0315","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1038\/s41467-022-34687-7","article-title":"Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia","volume":"13","author":"Sheikh","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0320","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1128\/IAI.00712-09","article-title":"Toxin-medicated effects on the innate mucosal defenses: Implications for enteric vaccines","volume":"77","author":"Glenn","year":"2009","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126828_bb0325","doi-asserted-by":"crossref","first-page":"e00215","DOI":"10.1128\/mSphere.00215-18","article-title":"The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126828_bb0330","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654872","article-title":"dmLT adjuvant enhances cytokine responses to T cell stimuli, whole cell vaccine antigens and lipopolysaccharide in both adults and infants","volume":"12","author":"Akhtar","year":"2021","journal-title":"Front Immunol"},{"issue":"12 Suppl 2","key":"10.1016\/j.vaccine.2025.126828_bb0340","doi-asserted-by":"crossref","first-page":"S821","DOI":"10.1093\/infdis\/jiab475","article-title":"Mucosal immune responses against an oral enterotoxigenic Escherichia coli vaccine evaluated in clinical trials","volume":"224","author":"Svennerholm","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126828_bb0345","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00565-23","article-title":"Cholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants","volume":"9","author":"Dash","year":"2024","journal-title":"mSphere"},{"issue":"14","key":"10.1016\/j.vaccine.2025.126828_bb0350","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.vaccine.2019.02.025","article-title":"Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge","volume":"37","author":"Harro","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126828_bb0355","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126828_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059822","article-title":"The mucosal adjuvant cholera toxin B instructs non-mucosal dendritic cells to promote IgA production via retinoic acid and TGF-\u03b2","volume":"8","author":"Gloudemans","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.126828_bb0365","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1128\/IAI.70.3.1056-1068.2002","article-title":"Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli","volume":"70","author":"Yu","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0370","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1189\/jlb.1103534","article-title":"Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent","volume":"75","author":"Lavelle","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126828_bb0375","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/mi.2017.70","article-title":"Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4+\u00a0T cells following parenteral immunization","volume":"11","author":"Frederick","year":"2018","journal-title":"Mucosal Immunol"},{"issue":"9888","key":"10.1016\/j.vaccine.2025.126828_bb0380","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126828_bb0385","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/21645515.2018.1496768","article-title":"Development of an enterotoxigenic\u00a0Escherichia coli vaccine based on the heat-stable toxin","volume":"15","author":"Zegeye","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"10.1016\/j.vaccine.2025.126828_bb0390","doi-asserted-by":"crossref","DOI":"10.1128\/aem.00959-22","article-title":"Evaluation of Multivalent Enterotoxigenic\u00a0Escherichia coli Vaccine Candidate MecVax Antigen Dose-Dependent Effect in a Murine Model","volume":"88","author":"Seo","year":"2022","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126828_bb0395","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01473-22","article-title":"Intramuscularly Administered Enterotoxigenic\u00a0Escherichia coli\u00a0(ETEC) Vaccine Candidate MecVax Prevented H10407 Intestinal Colonization in an Adult Rabbit Colonization Model","volume":"10","author":"Upadhyay","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2025.126828_bb0400","first-page":"86","author":"Nandre","year":"2018","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126828_bb0405","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/21645515.2018.1528410","article-title":"Update on Campylobacter vaccine development","volume":"15","author":"Poly","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126828_bb0410","article-title":"World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis","volume":"12","author":"Kirk","year":"2015","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126828_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002036","article-title":"Symptomatic and asymptomatic Campylobacter infections associated with reduced growth in Peruvian children","volume":"7","author":"Lee","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126828_bb0420","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/s41467-023-39433-1","article-title":"Campylobacter vaccination reduces diarrheal disease and infant growth stunting among rhesus macaques","volume":"14","author":"Hendrickson","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0425","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/iai.44.2.292-298.1984","article-title":"Human serum antibody response to Campylobacter jejuni infection as measured in an enzyme-linked immunosorbent assay","volume":"44","author":"Blaser","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0430","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/iai.43.3.986-993.1984","article-title":"Campylobacter jejuni outer membrane proteins are antigenic for humans","volume":"43","author":"Blaser","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0435","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1128\/IAI.67.11.5799-5805.1999","article-title":"Evaluation of a Truncated Recombinant Flagellin Subunit Vaccine against Campylobacter jejuni","volume":"67","author":"Lee","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0440","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1128\/iai.57.8.2542-2546.1989","article-title":"Georges Courbot MC Immune response to Campylobacter jejuni and Campylobacter coli in a cohort of children from birth to 2 years of age","volume":"57","author":"Martin","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0445","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1128\/jcm.21.1.33-38.1985","article-title":"Hart AM Western blot analysis of the human antibody response to Campylobacter jejuni cellular antigens during gastrointestinal infection","volume":"21","author":"Nachamkin","year":"1985","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126828_bb0450","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00430-007-0058-x","article-title":"Serological assessment of synthetic peptides of Campylobacter jejuni NCTC11168 FlaA protein using antibodies against multiple serotypes","volume":"197","author":"Fernando","year":"2008","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0455","first-page":"169","article-title":"Campylobacter Virulence Factors and Molecular Host-Pathogen Interactions","volume":"431","author":"Tegtmeyer","year":"2021","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126828_bb0460","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2019.12.064","article-title":"Mucosal delivery of live Lactococcus lactis expressing functionally active JlpA antigen induces potent local immune response and prevent enteric colonization of Campylobacter jejuni in chickens","volume":"38","author":"Gorain","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126828_bb0465","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1128\/JB.01542-09","article-title":"Specificity of the type II secretion systems of enterotoxigenic Escherichia coli and Vibrio cholerae for heat-labile enterotoxin and cholera toxin","volume":"192","author":"Mudrak","year":"2010","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0470","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1128\/IAI.00139-07","article-title":"Identification of a Campylobacter jejuni Protein That Cross-Reacts with Cholera Toxin","volume":"75","author":"Albert","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126828_bb0475","doi-asserted-by":"crossref","first-page":"e00246","DOI":"10.1128\/mBio.00246-13","article-title":"Oral Immunization with Cholera Toxin Provides Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model","volume":"4","author":"Albert","year":"2013","journal-title":"mBio"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126828_bb0480","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/CVI.00471-07","article-title":"Major outer membrane proteins from many Campylobacter species cross-react with cholera toxin","volume":"15","author":"Albert","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126828_bb0485","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1128\/CVI.00255-10","article-title":"Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model","volume":"17","author":"Islam","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0490","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.3390\/microorganisms11102414","article-title":"Efficacy of an Enterotoxigenic Escherichia coli (ETEC) Vaccine on the Incidence and Severity of Traveler\u2019s Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity Score","volume":"11","author":"Maier","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.126828_bb0495","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0140-6736(91)92590-X","article-title":"Prevention of travellers diarrhea by oral B-subunit\/whole cell cholera vaccine","volume":"338","author":"Peltola","year":"1991","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126828_bb0500","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1128\/JB.00042-12","article-title":"Characterization of the structurally diverse N-linked glycans of Campylobacter species","volume":"194","author":"Jervis","year":"2012","journal-title":"J Bacteriol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126828_bb0505","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1074\/mcp.M112.021519","article-title":"Diversity in the protein N-glycosylation pathways within the Campylobacter genus","volume":"11","author":"Nothaft","year":"2012","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126828_bb0510","article-title":"Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine","volume":"25","author":"Nothaft","year":"2016","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.vaccine.2025.126828_bb0515","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.01523-17","article-title":"Coadministration of the Campylobacter jejuni N-Glycan-Based Vaccine with Probiotics Improves Vaccine Performance in Broiler Chickens","volume":"83","author":"Nothaft","year":"2017","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.734526","article-title":"Improving Chicken Responses to Glycoconjugate Vaccination Against\u00a0Campylobacter jejuni","volume":"12","author":"Nothaft","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2025.126828_bb0525","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1021\/acschembio.1c00498","article-title":"Detecting Glucose fluctuations in Campylobacter jejuni N-Glycan structure","volume":"16","author":"Nothaft","year":"2021","journal-title":"ACS Chem Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:29:52Z","timestamp":1741793392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":105,"alternative-id":["S0264410X25001252"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126828","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conserved antigens for enteric vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126828"}}